Clinical

The CHHiP trial found fewer high-dose radiotherapy was as effective as more number of low-dose radiotherapy in men with prostate cancer.

An NCI-funded Breast Cancer Surveillance Consortium study has found that computer-aided detection and interpretation of mammograms does not add any value to breast cancer screening.

A prospective study that enrolled more than 10,000 women with hormone-receptor—positive, HER2-negative breast cancer has found that their response to a 21-gene test can identify patients who can avoid chemotherapy.

High-cost patients diagnosed with opioid abuse have higher rates of chronic comorbidities and mental health conditions compared with lower-cost patients, which highlights the need to consider the complete medical and psychosocial patient history, according to a new study published in the Journal of Managed Care & Specialty Pharmacy.

Palliative care should enter into the discussion with patients with cancer as early as possible as it can manage symptoms from therapy or it can provide comfort to patients who cannot afford or choose to forgo therapy, said Amy Davidoff, PhD, MS. Plus, she discusses the impact biosimilars may have on therapy costs.

Data presented at the ongoing European Cancer Congress has identified a different epigenetic profile in the tumors of younger colorectal cancer patients, information that can help improve treatment options in this population.

Eighty-six million US adults are at high risk of developing type 2 diabetes. Without prevention, there will be a drastic increase in the number of Americans who will develop type 2 diabetes.

Medicare beneficiaries undergoing dialysis who reach the Part D coverage gap have increased out-of-pocket spending, increased medical service utilization and costs, and increased mortality, according to a new study.

More than $100 million in Affordable Care Act funding is being awarded to 17 national, regional, and state hospital associations and health system organizations to assist efforts to reduce hospital-acquired conditions and readmissions.

Developed by Inovio Pharmaceuticals, the vaccine has shown the potential to impact precancerous cervical lesions.

The trial, conducted in France, was a proof-of-concept study to evaluate the efficacy of targeted agents in patients, based on their tumor's molecular profile.

Telehealth follow up consultations after a surgical operation have become preferred compared to in-person visits, according to 2 recent studies.

In a letter to Pathway Genomics, the FDA has expressed interest in discussing the company's validation strategy as well as evaluating data on clinical sensitivity and specificity of the CancerIntercept Detect test.

A study published in The Journal of Urology suggests the Grade D recommendation for PSA-based screening may place those with intermediate and high-risk prostate cancer at risk.

Public outrage over the 5000% price increase for Daraprim, a 62-year-old drug purchased by Turing Pharmaceuticals in August, prompted the company to promise it would lower the drug's cost. This is not the first time such an incidence has occurred.

Julie Vose, MD, MBA, FASCO, president of the American Society of Clinical Oncology and keynote speaker at Patient-Centered Oncology Care 2015, explains the importance of the meeting and how patients benefit when a diverse set of stakeholders come together in one room.

A JAMA Internal Medicine study found the terms "breakthrough" and "promising" raised people's expectations on the drug's performance as opposed to when the drugs were described as having met the breakthrough criteria.

A 3-year study of 200,000 Cigna customers has revealed just how expensive correctable health conditions can be and not knowing what health conditions they have can cost consumers even more.

A white paper released by QuantiaMD has identified a lack of awareness and education about biosimilars among prescribing physicians.

Lonsurf (TAS-102) is an oral 2-drug combination pill that is intended for metastatic colorectal cancer patients who have failed on chemotherapy and biological therapy.

Elise Berliner, PhD, director of the Technology Assessment Program in the Center for Outcomes and Evidence at the Agency for Healthcare Research and Quality, explains how the agency is using horizon scanning to peer into the future of treatments.

AstraZeneca hopes to harness the open source platform of the DREAM challenge, releasing preclinical data to discover synergistic cancer drug combinations.

Among other challenges faced by cancer care centers, reimbursement for providing patient-centered care services remains at the top, a survey by The Association of Community Cancer Centers found.

As the National Comprehensive Cancer Network (NCCN) celebrates 20 years, Clifford Goodman, PhD, takes a look at how NCCN will evolve after another 20 years, including constant streaming of real-time data and more patient involvement.

Researchers are proposing a new model to integrate clinical and community services for the purpose of preventing and controlling obesity, as well as related chronic diseases, such as type 2 diabetes.